Form 4: Krystal Biotech Director Suma Krishnan Sells Shares Under 10b5-1 Trading Plan

Suma Krishnan, a director and officer at Krystal Biotech, sold shares of common stock on March 11, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On March 11, 2024, Suma Krishnan, a Director and Officer (President, R&D) of Krystal Biotech, Inc. sold shares of the company's common stock.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan.
• Krishnan sold shares in multiple transactions at prices ranging from approximately $167.57 to $174.50.
• The spouse of Suma Krishnan, Krish S. Krishnan, also sold shares on the same day under a separate 10b5-1 trading plan.
• The spouse's sales were also executed in multiple transactions at prices ranging from approximately $167.49 to $174.50.
• Both trading plans started on September 11, 2023, and will terminate on September 11, 2024, contemplating sales of 25,000 shares per quarter with a limit price of $100.00 per share.
• Following the reported transactions, Suma Krishnan directly owns 1,550,882 shares of common stock and indirectly owns 1,752,262 shares through her spouse, SMK Trust, and Krishnan Family Trust.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to insider trading. It doesn't contain any information that would significantly impact investor sentiment positively or negatively. The sales are part of a pre-arranged plan, which reduces the likelihood of a strong market reaction.

Future Outlook

The 10b5-1 trading plans will continue to operate until September 11, 2024, potentially leading to further share sales by Suma Krishnan and Krish S. Krishnan, subject to the plan's terms.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity. It's common for executives and directors to use 10b5-1 trading plans to sell shares over time to avoid accusations of trading on inside information. The fact that both Suma and Krish S. Krishnan have active 10b5-1 plans suggests a planned and ongoing strategy for managing their Krystal Biotech holdings.

Comparison to Industry Standards

• It is common for executives at publicly traded companies, including those in the biotechnology sector like Amgen (AMGN) or Gilead Sciences (GILD), to utilize 10b5-1 trading plans for selling shares.
• The reported sales are within the typical range observed for insider transactions under such plans.
• The volume of shares sold is relatively small compared to the total outstanding shares of Krystal Biotech, suggesting it is unlikely to have a significant impact on the stock price.

Stakeholder Impact

• The share sales by a director and officer could be perceived negatively by some shareholders, but the existence of a 10b5-1 plan mitigates this concern.
• The impact on employees, customers, suppliers, and creditors is likely to be minimal.

Key Dates